Amgen announced positive topline results from its Phase 3 OASIZ 301 study for dazodalibep in Sjögren's disease, meeting its primary endpoint with statistically significant improvement. However, FDA approval is contingent on data from a second Phase 3 study (OASIZ 303), expected in Q4 2026, delaying potential market entry.
Amgen reported encouraging topline results for dazodalibep in its Phase 3 OASIZ 301 study for Sjögren's disease, a significant milestone given the historical difficulties in SjD drug development. This positive outcome validates Amgen's investment in the program and suggests potential for a new treatment option for patients. However, the immediate market impact is tempered by the requirement for a second positive Phase 3 study (OASIZ 303) before an FDA filing can occur, pushing out the timeline for potential approval and commercialization to late 2026 or beyond. This creates a short-term opportunity for investors to react to the positive clinical data, but also a long-term risk associated with the outcome of the second trial and the extended approval timeline.